Idioma:

Use of Octreotide for the Prevention of Pancreatic Fistula After Elective Pancreatic Surgery: A Systematic Review and Meta-Analysis

Alghamdi, Abdullah A., MD ; Jawas, Ali M., MD ; Hart, Richard S., MD

Canadian Journal of Surgery, 2007-12, Vol.50 (6), p.459-466 [Periódico revisado por pares]

Canada: Joule Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Use of Octreotide for the Prevention of Pancreatic Fistula After Elective Pancreatic Surgery: A Systematic Review and Meta-Analysis
Autor: Alghamdi, Abdullah A., MD ; Jawas, Ali M., MD ; Hart, Richard S., MD
Assuntos: Aged ; Antimitotic agents ; Antineoplastic agents ; Clinical trials ; Complications ; Dosage and administration ; Elective Surgical Procedures - adverse effects ; Fistula ; Gastrointestinal Agents - therapeutic use ; Humans ; Meta-analysis ; Middle Aged ; Octreotide - therapeutic use ; Pancreas ; Pancreatectomy - adverse effects ; Pancreatic diseases ; Pancreatic Fistula - etiology ; Pancreatic Fistula - prevention & control ; Peptides ; Prevention ; Review ; Studies ; Surgery ; Treatment Outcome
É parte de: Canadian Journal of Surgery, 2007-12, Vol.50 (6), p.459-466
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
Descrição: Objective To assess the effectiveness of octreotide in preventing postoperative pancreatic fistula. Pancreatic fistula is one of the most common complications after elective pancreatic surgery. Several clinical trials have evaluated the use of octreotide to prevent the development of pancreatic fistula after pancreatic surgery with conflicting recommendations. Methods We undertook a meta-analysis of 7 identified randomized controlled trials, reporting comparisons between octreotide and a control. The primary outcome was the incidence of postoperative pancreatic fistula, and the secondary outcome was the postoperative mortality. Results Seven studies, involving 1359 patients, met the inclusion criteria for this review. In these studies, sample sizes ranged from 75 to 252 patients. In total, 679 patients were given octreotide and 680 patients formed the control group. Perioperative octreotide is associated with a significant reduction in the incidence of pancreatic fistula after elective pancreatic surgery, with a relative risk of 0.59 (95% confidence interval 0.41–0.85, p = 0.004). However, this risk reduction was not associated with a significant difference in postoperative mortality ( p > 0.05). Conclusions The review revealed that perioperative octreotide is associated with a significant reduction in the incidence of pancreatic fistula after elective pancreatic surgery. However, this risk reduction was not associated with a significant difference in postoperative mortality; further studies are warranted to confirm the results of this metaanalysis and to define which patient subgroups might benefit the most from prophylactic octreotide administration.
Editor: Canada: Joule Inc
Idioma: Francês;Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Use of Octreotide for the Prevention of Pancreatic Fistula After Elective Pancreatic Surgery: A Systematic Review and Meta-Analysis

Alghamdi, Abdullah A., MD ; Jawas, Ali M., MD ; Hart, Richard S., MD

Canada: Joule Inc

Buscando em bases de dados remotas. Favor aguardar.